Physician profile
Santosh Kumar
NPI 1265695241
$2,548.45
in general payments reported to CMS, 2019-2025
31 companies · $21.59 in 2025
The $21.59 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $533 · 2021: $869 · 2022: $1,075 · 2023: $29.70 · 2024: $19.30 · 2025: $21.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $70.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $70.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $499.37 | 2021-2025 | |
| Amgen INC. | $333.25 | 2020-2022 | |
| Novo Nordisk INC | $307.78 | 2020-2022 | |
| Lilly USA, LLC | $189.71 | 2021-2022 | |
| Glaxosmithkline, LLC. | $160.86 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $115.48 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $105.88 | 2021-2022 | |
| Mylan Specialty L.P. | $100.08 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $68.98 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $63.76 | 2020-2022 | |
| Astrazeneca Pharmaceuticals Lp | $57.49 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $57.38 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $52.15 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $46.94 | 2020-2022 | |
| Pfizer INC. | $38.06 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $34.69 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $34.29 | 2020-2022 | |
| Axsome Therapeutics, INC. | $33.81 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $33.44 | 2022 | |
| Allergan, INC. | $28.57 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.24 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $23.28 | 2022 | |
| Medicure Pharma INC. | $19.20 | 2022 | |
| Sanofi-Aventis U.S. LLC | $17.19 | 2021 | |
| Esperion Therapeutics, INC. | $16.47 | 2020 | |
| Insulet Corporation | $15.42 | 2023 | Omnipod |
| Ultragenyx Pharmaceutical INC. | $15.34 | 2022 | |
| Astellas Pharma US INC | $15.15 | 2021 | |
| Lundbeck LLC | $13.15 | 2022 | |
| Acadia Pharmaceuticals INC | $12.80 | 2020 | |
| Idorsia Pharmaceuticals US INC | $12.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Santosh Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.